Impact of autologous mitochondrial transfer on obstetric and neonatal health of offspring: A small single-center case series

IF 3 2区医学 Q2 DEVELOPMENTAL BIOLOGY

Placenta Pub Date : 2024-10-15 DOI:10.1016/j.placenta.2024.10.007

Julia Gil , Mar Nohales , David Ortega-Jaen , Angel Martin , M.L. Pardiñas , Vicente Serra , Elena Labarta , Maria José de los Santos

{"title":"Impact of autologous mitochondrial transfer on obstetric and neonatal health of offspring: A small single-center case series","authors":"Julia Gil , Mar Nohales , David Ortega-Jaen , Angel Martin , M.L. Pardiñas , Vicente Serra , Elena Labarta , Maria José de los Santos","doi":"10.1016/j.placenta.2024.10.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>A pilot study was carried out to test the efficacy of the autologous mitochondrial transfer therapy (AUGMENT) technique. No improvements in pregnancy rate, development, or embryo quality were observed in the AUGMENT-treated group versus the Control group in this study. The main objective of this research is to analyze whether AUGMENT technology did have any impact on the obstetric and perinatal outcomes of pregnancies and children resulting from treated oocytes.</div></div><div><h3>Methods</h3><div>Follow up study of women with a livebirth who participated in a pilot randomized controlled trial in which sibling MII oocytes were randomly allocated to AUGMENT + intracytoplasmic sperm injection (ICSI) (AUGMENT group) or ICSI alone (control group). Preimplantation genetic testing for aneuploidy was performed in both groups. Pregnancy and neonatal outcomes of 14 women (15 pregnancies) and their 18 children were analyzed. The information was retrieved by reviewing the medical records or through questionnaires sent to the patients.</div></div><div><h3>Results</h3><div>No differences were found in this small case series between the AUGMENT and control groups regarding the rate of gestational complications, birth defects, gestational age at delivery (271.4 ± 12.56 vs 278 ± 10.4 days), birthweight (3.1 ± 0.6 kg vs. 3.1 ± 0.4 kg) and neonatal outcome.</div></div><div><h3>Discussion</h3><div>The few pregnancies achieved using AUGMENT oocyte therapy had similar outcomes than controls in this very small series. Our very preliminary data need to be confirmed in larger samples. The long term follow up of these children also needs to be analyzed.</div></div>","PeriodicalId":20203,"journal":{"name":"Placenta","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Placenta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0143400424006775","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

A pilot study was carried out to test the efficacy of the autologous mitochondrial transfer therapy (AUGMENT) technique. No improvements in pregnancy rate, development, or embryo quality were observed in the AUGMENT-treated group versus the Control group in this study. The main objective of this research is to analyze whether AUGMENT technology did have any impact on the obstetric and perinatal outcomes of pregnancies and children resulting from treated oocytes.

Methods

Follow up study of women with a livebirth who participated in a pilot randomized controlled trial in which sibling MII oocytes were randomly allocated to AUGMENT + intracytoplasmic sperm injection (ICSI) (AUGMENT group) or ICSI alone (control group). Preimplantation genetic testing for aneuploidy was performed in both groups. Pregnancy and neonatal outcomes of 14 women (15 pregnancies) and their 18 children were analyzed. The information was retrieved by reviewing the medical records or through questionnaires sent to the patients.

Results

No differences were found in this small case series between the AUGMENT and control groups regarding the rate of gestational complications, birth defects, gestational age at delivery (271.4 ± 12.56 vs 278 ± 10.4 days), birthweight (3.1 ± 0.6 kg vs. 3.1 ± 0.4 kg) and neonatal outcome.

Discussion

The few pregnancies achieved using AUGMENT oocyte therapy had similar outcomes than controls in this very small series. Our very preliminary data need to be confirmed in larger samples. The long term follow up of these children also needs to be analyzed.

查看原文本刊更多论文

自体线粒体移植对后代产科和新生儿健康的影响：小型单中心病例系列

导言：为测试自体线粒体移植疗法（AUGMENT）的疗效，我们开展了一项试验性研究。在这项研究中，AUGMENT治疗组与对照组相比，在妊娠率、发育和胚胎质量方面均未见改善。本研究的主要目的是分析 AUGMENT 技术是否会对经过处理的卵母细胞所产生的妊娠和婴儿的产科和围产期结果产生影响。方法：对参加试点随机对照试验的活产妇女进行跟踪研究，在该试验中，同胞 MII 卵母细胞被随机分配到 AUGMENT + 卵胞浆内单精子注射（ICSI）（AUGMENT 组）或单精子卵胞浆内单精子注射（ICSI）（对照组）。两组均进行了植入前非整倍体基因检测。对 14 名妇女（15 次妊娠）及其 18 名子女的妊娠和新生儿结局进行了分析。结果在这个小型病例系列中，AUGMENT 组和对照组在妊娠并发症发生率、出生缺陷、胎龄（271.讨论在这个非常小的系列中，使用 AUGMENT 卵母细胞疗法的少数孕妇与对照组的结果相似。我们的初步数据需要在更大的样本中得到证实。此外，还需要对这些患儿的长期随访情况进行分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Placenta 医学-发育生物学

CiteScore

6.30

自引率

10.50%

发文量

391

审稿时长

78 days

期刊介绍： Placenta publishes high-quality original articles and invited topical reviews on all aspects of human and animal placentation, and the interactions between the mother, the placenta and fetal development. Topics covered include evolution, development, genetics and epigenetics, stem cells, metabolism, transport, immunology, pathology, pharmacology, cell and molecular biology, and developmental programming. The Editors welcome studies on implantation and the endometrium, comparative placentation, the uterine and umbilical circulations, the relationship between fetal and placental development, clinical aspects of altered placental development or function, the placental membranes, the influence of paternal factors on placental development or function, and the assessment of biomarkers of placental disorders.